NIH R01 · 2025
PROJECT SUMMARY Immune checkpoint inhibitors (ICI) are monoclonal antibodies that block regulators of T cell activation, activating anti-cancer immunity and greatly improving overall survival in patients with advanced cancer. However, ICI commonly cause immune related adverse events (irAE), including inflammatory arthritis (ICI-IA). It is estimated that as many as 14,000 ICI-treated patients will develop ICI-IA each year. ICI-IA can i. be destructive to the joint, ii. persist for months to years, and iii. require treatment with glucocorticoids and immunosuppressive disease modifying antirheumatic drugs (DMARDs). However, immunosuppression may worsen cancer survival in this setting.…
From the public funding record at NIH RePORTER. Describes the funded project, not the reviews below.